REG - Hikma Pharmaceutical - Result of AGM

Hikma PharmaceuticalsAnnouncement

24/04/2025 16:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250424:nRSX1101Ga&default-theme=true

RNS Number : 1101G  Hikma Pharmaceuticals Plc  24 April 2025

Hikma Pharmaceuticals PLC

Results of 2025 Annual General Meeting

LONDON, 24 April 2025 Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK)
(OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (the 'Company' or 'Hikma') announces
that its Annual General Meeting ('AGM') was held at Sofitel London St James, 6
Waterloo Place, London SW1Y 4AN earlier today (24 April 2025) and commenced at
11.30 am. All the proposed resolutions were duly passed by shareholders by way
of a poll. Resolutions 1 to 16 (inclusive) were passed as ordinary resolutions
and Resolutions 17 to 20 (inclusive) were passed as special resolutions.
Resolutions 21 to 22 (inclusive) were passed as ordinary resolutions on which
only Independent Shareholders (that is, excluding members of the Darhold
Concert Party, in accordance with the City Code on Takeovers and Mergers) were
entitled to vote.

Copies of the resolutions dealing with special business passed at the AGM have
been submitted to the FCA's Electronic Submission System and will be available
from the National Storage Mechanism. Capitalised terms used but not otherwise
defined in this announcement shall have the meanings given to them in the
Notice of Meeting dated 19 March 2025.

The total number of votes cast on the poll for each resolution (the full text
of the resolutions is detailed in the Notice of Meeting dated 19 March 2025)
is set out below. The number of Ordinary Shares in issue at the close of
business on 22 April 2025 was 234,719,686.  At that time there were
12,833,233 Ordinary Shares held in treasury, which are not counted in the
voting capital of the Company which, therefore, was 221,886,453.

 Resolution                                                                    Votes For    % of Eligible Votes  Votes Against  % of Eligible Votes  Total Votes Cast  Total votes cast as a % of ISC(1)  Withheld(2)
 1. To receive the 2024 report and accounts                                    165,916,947  99.98%                25,032        0.02%                165,941,979       74.79%                             1,306,504
 2. To approve a final dividend of 48 cents per share                          167,236,391  99.99%                101           0.01%                167,236,492       75.37%                             11,991
 3. To re-appoint PricewaterhouseCoopers LLP as Auditor                        165,736,140  99.80%                324,240       0.20%                166,060,380       74.84%                             1,188,103
 4. To authorise the Audit Committee to determine the remuneration of the      166,976,846  99.84%                259,630       0.16%                167,236,476       75.37%                             12,007
 Auditor
 5. To re-elect Said Darwazah as a Director                                    159,872,112  96.63%                5,581,855     3.37%                165,453,967       74.57%                             1,794,516
 6. To re-elect Riad Mishlawi as a Director                                    165,620,901  99.04%                1,612,530     0.96%                167,233,431       75.37%                             15,052
 7. To re-elect Mazen Darwazah as a Director                                   158,508,255  95.06%                8,244,567     4.94%                166,752,822       75.15%                             495,661
 8. To re-elect Victoria Hull as a Director                                    164,823,607  98.84%                1,929,924     1.16%                166,753,531       75.15%                             494,952
 9. To re-elect Ali Al-Husry as a Director                                     165,206,365  98.86%                1,903,076     1.14%                167,109,441       75.31%                             139,042
 10. To re-elect Nina Henderson as a Director                                  166,343,333  99.47%                891,330       0.53%                167,234,663       75.37%                             13,820
 11. To re-elect Cynthia Flowers as a Director                                 166,327,864  99.46%                906,799       0.54%                167,234,663       75.37%                             13,820
 12. To re-elect Douglas Hurt as a Director                                    166,338,974  99.47%               894,533        0.53%                167,233,507       75.37%                             14,976
 13. To re-elect Laura Balan as a Director                                     166,404,839  99.50%               829,824        0.50%                167,234,663       75.37%                             13,820
 14. To re-elect Dr Deneen Vojta as a Director                                 166,339,842  99.46%               894,796        0.54%                167,234,638       75.37%                             13,845
 15. To receive and approve the annual report on Remuneration                  165,314,532  99.55%               745,734        0.45%                166,060,266       74.84%                             1,188,217
 16. To authorise the Directors to allot shares and grant rights to subscribe  161,367,208  96.49%               5,868,306      3.51%                167,235,514       75.37%                             12,969
 for shares
 17. To authorise the disapplication of pre-emption rights (General)           159,795,080  95.55%               7,438,019      4.45%                167,233,099       75.37%                             15,384
 18. To authorise the disapplication of pre-emption rights (Acquisition or     150,608,461  90.06%               16,626,673     9.94%                167,235,134       75.37%                             13,349
 Capital Investment)
 19. To authorise the Company to purchase Ordinary Shares                      165,666,195  99.21%               1,314,296      0.79%                166,980,491       75.25%                             267,992
 20. To authorise the Company to hold general meetings on not less than 14     161,269,635  96.43%               5,966,422      3.57%                167,236,057       75.37%                             12,426
 clear days' notice
 21. To approve the Rule 9 Waiver (Buyback Waiver)(3)                          103,445,950  93.41%               7,303,834      6.59%                110,749,784       49.91%                             3,164,163
 22. To approve the Rule 9 Waiver (2026 Awards Waiver)(3)                      105,601,900  95.35%               5,145,069      4.65%                110,746,969       49.91%                             3,166,978

 

(1) Issued Ordinary Share capital of the Company (excluding treasury shares).

(2) A "withheld" vote is not a vote in law and is not counted in the
calculation of the proportion of votes "for" or "against" a resolution.

(3) In order to comply with the City Code on Takeovers and Mergers, only the
votes cast by the independent shareholders were counted for the purposes of
Resolutions 21 to 22.

 

Declaration of final dividend

The dividend of 48 cents per share will be paid on 1 May 2025 to shareholders
on the register at the close of business on 21 March 2025. Shareholders who
are not resident in Jordan have been given the option of receiving their
dividend in Pounds Sterling. The exchange rate in respect of this dividend
will be $1.29 to £1. The exchange rate for Jordanian Dinar is fixed to the US
Dollar at circa $1 to 0.708JD.

 

- ENDS -

 

Enquiries:

 

 Hikma Pharmaceuticals PLC
 Helen Middlemist           +44 20 7399 2670

 Group Company Secretary

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGSEDFLLEISEIL